Infliximab versus Cyclophosphamide for Severe Behçet’s Syndrome
Among patients with severe Behçet's syndrome, induction therapy with infliximab had a superior complete response rate at 22 weeks and fewer adverse events than induction with cyclophosphamide. (Funded by the French Ministry of Health.).
Authors
- Tristan Mirault (ORCID: https://orcid.org/0000-0001-8690-1093)
- Matheus Vieira (ORCID: https://orcid.org/0000-0003-4588-0403)
- Aurélie Plessier (ORCID: https://orcid.org/0000-0001-5656-1622)
- Isabelle Melki (ORCID: https://orcid.org/0000-0002-8057-333X)
- Alban Redheuil (ORCID: https://orcid.org/0000-0002-1002-9902)
- Matthieu Resche‐Rigon (ORCID: https://orcid.org/0000-0003-2220-5085)
- A.C. Desbois (ORCID: https://orcid.org/0000-0002-4638-1238)
- Georgina Maalouf (ORCID: https://orcid.org/0000-0002-4554-1922)
- Élisabeth Maillart (ORCID: https://orcid.org/0000-0001-7699-0328)
- Isabelle Koné‐Paut (ORCID: https://orcid.org/0000-0001-8939-5763)
- Azeddine Dellal
- P. Cacoub (ORCID: https://orcid.org/0000-0002-6727-4992)
- Thomas Sené (ORCID: https://orcid.org/0000-0002-3162-2537)
- F. Domont
- S. Trad (ORCID: https://orcid.org/0000-0001-8927-9180)
- Karim Sacré (ORCID: https://orcid.org/0000-0002-6544-234X)
- Jean‐François Viallard (ORCID: https://orcid.org/0000-0001-7500-9323)
- Julien Gaudric (ORCID: https://orcid.org/0000-0003-0875-1442)
- Gaëlle Leroux (ORCID: https://orcid.org/0000-0003-2729-4945)
- Adrien Mirouse (ORCID: https://orcid.org/0000-0002-5755-8043)
- Mathieu Vautier (ORCID: https://orcid.org/0000-0003-2386-9609)
- Aude Rigolet (ORCID: https://orcid.org/0000-0003-2381-793X)
- Nicolas Noël (ORCID: https://orcid.org/0000-0003-4055-617X)
- Amine Ghembaza (ORCID: https://orcid.org/0000-0003-1519-2028)
- Yasmina Ferfar
- Estibaliz Lazaro (ORCID: https://orcid.org/0000-0002-4206-7399)
- Nicolas Mêlé (ORCID: https://orcid.org/0000-0001-5390-401X)
- David Saadoun (ORCID: https://orcid.org/0000-0003-3628-9996)
- A. Mékinian (ORCID: https://orcid.org/0000-0003-2849-3049)
- Emmanuel Ribeiro
- Laurent Chiche (ORCID: https://orcid.org/0000-0002-0582-694X)
- Olivier Fain
- Marc Lambert
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Hôpital Beaujon (FR)
- Saint Louis University Hospital (US)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre François Baclesse (LU)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Saint-Antoine (FR)
- Bordeaux Population Health (FR)
- Hôpital Saint-André (FR)
- Immunology from Concept and Experiments to Translation (FR)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier Sainte-Anne (FR)
- Centre de Recherche sur l'Inflammation (FR)
- Paris Cardiovascular Research Center (FR)
- Hôpital Ambroise-Paré (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Fondation pour l’innovation en Cadiométabolisme et Nutrition (FR)
- Hôpital Claude Huriez (FR)
- Groupe Hospitalier Intercommunal Le Raincy Montfermeil (FR)
- Bicêtre Hospital (FR)
- Immunologie - Immunopathologie - Immunothérapie (FR)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1056/evidoa2300354
- Citations
- 29
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 15.62